Advertisement

Modeling the Impacts of Price of an Over-the-Counter Progestin-Only Pill on Use and Unintended Pregnancy among U.S. Women

Published:April 13, 2020DOI:https://doi.org/10.1016/j.whi.2020.01.003

      Abstract

      Objective

      To model the impacts of out-of-pocket cost of an over-the-counter (OTC) progestin-only pill on use and associated unintended pregnancy among U.S. women.

      Study Design

      Using data from a 2015 nationally representative survey of 2,539 U.S. women aged 15 to 44 assessing interest in using an OTC progestin-only pill, we used discrete survival analysis and a Markov model to analyze women's likelihood of using of an OTC pill at different price points and by sociodemographic characteristics. We modeled the impact of product price on the potential total number of U.S. users and on unintended pregnancies in 1 year among adult women at risk of unintended pregnancy.

      Results

      In a model assuming no out-of-pocket costs, more than 12.5 million adults and 1.75 million teens reported likely use of an OTC progestin-only pill if available. Among adults, this resulted in an estimated 8% decrease in unintended pregnancy in 1 year. Adult and teen women on average were willing to pay $15 and $10, respectively, resulting in 7.1 million adult and 1.3 million teen users and an estimated 5% decrease in unintended pregnancy among adults.

      Conclusions

      At low and no out-of-pocket cost, a large population of women in the United States might likely use an OTC progestin-only pill. A low retail price and insurance coverage are necessary to provide equitable access to this method for low-income populations across the United States, fill current gaps in contraceptive access, and potentially decrease unintended pregnancy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Women's Health Issues
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barker J.
        • Williamson J.
        • Fahey J.
        House Bill 3391.
        Pub. L. No. 3391- B, 2017
        • Bureau of the Census for the Bureau of Labor Statistics
        Current population survey supplement data.
        Author, Washington, DC2014
        • Foster D.G.
        • Biggs M.A.
        • Phillips K.A.
        • Grindlay K.
        • Grossman D.
        Potential public sector cost-savings from over-the-counter access to oral contraceptives.
        Contraception. 2015; 91: 373-379
        • Frost J.J.
        • Singh S.
        • Finer L.B.
        U.S. women’s one-year contraceptive use patterns, 2004.
        Perspectives on Sexual and Reproductive Health. 2007; 39: 48-55
        • Grimes D.A.
        • Lopez L.M.
        • O’Brien P.A.
        • Raymond E.G.
        Progestin-only pills for contraception.
        The Cochrane Database of Systematic Reviews. 2010; 1: CD007541
        • Grindlay K.
        • Grossman D.
        Prescription birth control access among U.S. women at risk of unintended pregnancy.
        Journal of Women’s Health (2002). 2016; 25: 249-254
        • Grindlay K.
        • Grossman D.
        Interest in over-the-counter access to a progestin-only pill among women in the United States.
        Women’s Health Issues. 2018; 28: 144-151
        • Grossman D.
        • Grindlay K.
        • Li R.
        • Potter J.E.
        • Trussell J.
        • Blanchard K.
        Interest in over-the-counter access to oral contraceptives among women in the United States.
        Contraception. 2013; 88: 544-552
        • Jackson E.
        • Glasier A.
        Return of ovulation and menses in postpartum nonlactating women: a systematic review.
        Obstetrics and Gynecology. 2011; 117: 657-662
        • Jones R.K.
        • Darroch J.E.
        • Henshaw S.K.
        Contraceptive use among U.S. women having abortions in 2000-2001.
        Perspectives on Sexual and Reproductive Health. 2002; 34: 294-303
        • Kelly A.
        Maryland House Bill 10005: Contraceptive Equity Act.
        Pub. L. No. 1005, 2016
        • Knowledge Networks
        Knowledge Panel design summary.
        Growth from Knowledge, Palo Alto, CA2013
        • Landau S.C.
        • Tapias M.P.
        • McGhee B.T.
        Birth control within reach: a national survey on women’s attitudes toward and interest in pharmacy access to hormonal contraception.
        Contraception. 2006; 74: 463-470
        • Liang S.-Y.
        • Grossman D.
        • Phillips K.A.
        User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives.
        Contraception. 2012; 86: 666-672
        • Lumley T.
        Survey: Analysis of complex survey samples.
        Journal of Statistical Software. 2004; 9: 1-19
        • National Center for Health Statistics
        2013-2015 National Survey of Family Growth.
        Centers for Disease Control and Prevention, Atlanta2016
        • Nekritz E.
        • Wallace L.
        • Tabares S.
        Illinois HB5576: Ins CD-Contraceptive Coverage.
        2016
        • Potter J.E.
        • McKinnon S.
        • Hopkins K.
        • Amastae J.
        • Shedlin M.G.
        • Powers D.A.
        • Grossman D.
        Continuation of prescribed compared with over-the-counter oral contraceptives.
        Obstetrics and Gynecology. 2011; 117: 551-557
        • Rao J.N.K.
        • Wu C.F.J.
        Resampling inference with complex survey data.
        Journal of the American Statistical Association. 1988; 83: 231-241
        • Sonfield A.
        • Hasstedt K.
        • Gold R.B.
        Moving forward: Family planning in the era of health reform.
        (Available:) (Accessed: june 31, 2019)
        • Trussell J.
        Contraceptive failure in the United States.
        Contraception. 2011; 83: 397-404
        • U.S. Census Bureau
        American Community Survey.
        U.S. Census Bureau, Washington, DC2013
        • U.S. Census Bureau, Population Division
        Annual estimates of the resident population by sex, single year of age, race, and Hispanic origin for the United States: April 1, 2010 to July 1, 2016.
        U.S. Census Bureau, Washington, DC2017
        • Vaughan B.
        • Trussell J.
        • Kost K.
        • Singh S.
        • Jones R.
        Discontinuation and resumption of contraceptive use: Results from the 2002 National Survey of Family Growth.
        Contraception. 2008; 78: 271-283
        • White K.
        • Potter J.E.
        • Hopkins K.
        • Fernández L.
        • Amastae J.
        • Grossman D.
        Contraindications to progestin-only oral contraceptive pills among reproductive aged women.
        Contraception. 2012; 86: 199-203
        • Wu C.F.J.
        • Rao J.N.K.
        • Yue K.
        Survey methodology: Some recent work on resampling methods for complex surveys.
        (Available:)

      Biography

      Alexandra Wollum, MPH, is a Senior Project Manager at Ibis Reproductive Health. Her research focuses on improving reproductive health in underserved communities and exploring innovative approaches to increase reproductive health access.

      Biography

      James Trussell, PhD, was emeritus professor of Public and International Affairs at Princeton University. He authored or co-authored more than 350 scientific publications, primarily in the areas of reproductive health and demographic methodology.

      Biography

      Daniel Grossman, MD, is the Director of Advancing New Standards in Reproductive Health at the University of California, San Francisco. His research focuses on improving access to contraception and safe abortion and evaluating the impact of integrating reproductive health and HIV services.

      Biography

      Kate Grindlay, MSPH, is an Associate at Ibis Reproductive Health and Project Director of the Free the Pill project. She oversees the implementation of a program to move an oral contraceptive pill over the counter in the United States.